HUMA - Humacyte, Inc.
IEX Last Trade
5.2
-0.005 -0.096%
Share volume: 412,374
Last Updated: Thu 26 Dec 2024 08:30:28 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$5.20
0.00
-0.10%
Fundamental analysis
13%
Profitability
0%
Dept financing
14%
Liquidity
75%
Performance
11%
Performance
5 Days
-3.01%
1 Month
1.81%
3 Months
-17.55%
6 Months
-9.80%
1 Year
54.98%
2 Year
118.93%
Key data
Stock price
$5.20
DAY RANGE
$4.47 - $5.25
52 WEEK RANGE
$2.58 - $9.97
52 WEEK CHANGE
$51.85
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Laura E. Niklason
Region: US
Website: humacyte.com
Employees: 150
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: humacyte.com
Employees: 150
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues. Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company was founded in 2004 and is headquartered in Durham, North Carolina.
Recent news